Media coverage about MYOS RENS Technology (NASDAQ:MYOS) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. MYOS RENS Technology earned a coverage optimism score of 0.19 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.9221277166959 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Separately, ValuEngine cut MYOS RENS Technology from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 12th.

MYOS RENS Technology (MYOS) traded up 0.76% during mid-day trading on Monday, reaching $1.33. The company had a trading volume of 3,300 shares. The company’s 50 day moving average is $1.73 and its 200 day moving average is $2.39. MYOS RENS Technology has a 52-week low of $1.02 and a 52-week high of $6.98. The stock’s market capitalization is $7.77 million.

ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect MYOS RENS Technology (MYOS) Stock Price” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/21/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-myos-rens-technology-myos-stock-price.html.

About MYOS RENS Technology

MYOS RENS Technology Inc (MYOS), formerly MYOS Corporation, is an early-stage bionutrition and biotherapeutics company. The Company is focused on the discovery, development and commercialization of products that improve muscle health and function essential for the management of sarcopenia, cachexia and degenerative muscle diseases, and as an adjunct to the treatment of obesity.

Insider Buying and Selling by Quarter for MYOS RENS Technology (NASDAQ:MYOS)

Receive News & Stock Ratings for MYOS RENS Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYOS RENS Technology Inc. and related stocks with our FREE daily email newsletter.